Zobrazeno 1 - 10
of 226
pro vyhledávání: '"M, Walko"'
Autor:
Michael J. Fusco PharmD, Yolanda Piña MD, Robert J. Macaulay MD, Solmaz Sahebjam MD, Peter A. Forsyth MD, Edwin Peguero MD, Christine M. Walko PharmD
Publikováno v:
Cancer Control, Vol 28 (2021)
Introduction BRAF V600 E mutations have been identified in a subset of patients with primary brain tumors. Combination therapy with BRAF and Mitogen-activated protein kinase (MEK) inhibitors (BRAF/MEKi) targeting sequential steps in the MAPK pathway
Externí odkaz:
https://doaj.org/article/4ed7e257a9e5442fa50f23830b88c293
Autor:
Sharyn D. Baker, Susan E. Bates, Gabriel A. Brooks, William L. Dahut, Robert B. Diasio, Wafik S. El-Deiry, William E. Evans, William D. Figg, Dan L. Hertz, J. Kevin Hicks, Suneel Kamath, Pashtoon Murtaza Kasi, Todd C. Knepper, Howard L. McLeod, Peter H. O'Donnell, Mary V. Relling, Michelle A. Rudek, Tristan M. Sissung, D. Max Smith, Alex Sparreboom, Sandra M. Swain, Christine M. Walko
Publikováno v:
Journal of Clinical Oncology. 41:2701-2705
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bd1750e4c05931efd2a32d144bd9ec0
https://doi.org/10.1200/jco.22.02364
https://doi.org/10.1200/jco.22.02364
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Eric Padron, D. Neil Hayes, Ahmet Zehir, Elli Papaemmanuil, Ross L. Levine, H. Shelton Earp, William Y. Kim, Juneko E. Grilley-Olson, Jared Weiss, John T. Soper, Todd C. Knepper, Christine M. Walko, Kristy L. Richards, Nirali M. Patel, Michele C. Hayward, Sean J. Yoder, Tania E. Mesa, Joel S. Parker, Kelly L. Bolton, Nathan D. Montgomery, Maria E. Balasis, Markus Ball, Jonathan S. Berg, Xianming Tan, Nancy K. Gillis, Catherine C. Coombs
Purpose:In this era of precision-based medicine, for optimal patient care, results reported from commercial next-generation sequencing (NGS) assays should adequately reflect the burden of somatic mutations in the tumor being sequenced. Here, we sough
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dc8a460255a9413c3920f646bb3a6eb
https://doi.org/10.1158/1078-0432.c.6527667.v1
https://doi.org/10.1158/1078-0432.c.6527667.v1
Autor:
Eric Padron, D. Neil Hayes, Ahmet Zehir, Elli Papaemmanuil, Ross L. Levine, H. Shelton Earp, William Y. Kim, Juneko E. Grilley-Olson, Jared Weiss, John T. Soper, Todd C. Knepper, Christine M. Walko, Kristy L. Richards, Nirali M. Patel, Michele C. Hayward, Sean J. Yoder, Tania E. Mesa, Joel S. Parker, Kelly L. Bolton, Nathan D. Montgomery, Maria E. Balasis, Markus Ball, Jonathan S. Berg, Xianming Tan, Nancy K. Gillis, Catherine C. Coombs
Supplementary data file
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01afee6ef430f84be47a04bf420c9855
https://doi.org/10.1158/1078-0432.22470726.v1
https://doi.org/10.1158/1078-0432.22470726.v1
Autor:
Jamie K. Teer, Dae-Won Kim, Estrella Carballido, Martine Extermann, J. Kevin Hicks, Daryoush Saeed-Vafa, Kirsten Blue, Todd C. Knepper, Howard L. McLeod, Theresa A. Boyle, Jason B. Fleming, Michael J Fusco, Christine M. Walko, Mokenge P. Malafa
Publikováno v:
JCO Precision Oncology. :65-74
PURPOSEIt has recently been described that alternative oncogenic drivers may be found in KRAS wild-type ( KRASWT) pancreatic cancers. This study aimed to determine the incidence of targetable gene fusions present in KRASWTpancreatic adenocarcinoma an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65f081e9b419804206fd496f5efa8db2
https://doi.org/10.1200/po.20.00265
https://doi.org/10.1200/po.20.00265
Autor:
Rachel Hagyeong Yang, Julie W. Stephens, Rebecca S. Pettit, Kristin Wiisanen, Roseann S. Gammal, D. Max Smith, Henry M. Dunnenberger, Joseph M. Cusimano, Christine M. Walko
Publikováno v:
JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 4:652-658
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa7247a4654ad67dd2526e733375406f
https://doi.org/10.1002/jac5.1437
https://doi.org/10.1002/jac5.1437
Autor:
Canan Karan, Elaine Tan, Humaira Sarfraz, Todd C. Knepper, Christine M. Walko, Seth Felder, Richard Kim, Ibrahim Halil Sahin
Publikováno v:
JCO oncology practice. 18(8)
The treatment paradigm for colorectal cancer (CRC) has changed significantly over the past decade with targeted therapeutics. Human epidermal growth factor receptor 2 ( HER2) amplification is seen among 3%-4% of patients with metastatic CRC (mCRC). T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f8104d7f8bed824301233ec5b08818e
https://pubmed.ncbi.nlm.nih.gov/35947878
https://pubmed.ncbi.nlm.nih.gov/35947878
Autor:
Solmaz Sahebjam, Sungjune Kim, Melissa Wicklund, Brittany Evernden, Christine M. Walko, Hsiang-Hsuan Michael Yu, Prakash Chinnaiyan, Zachary J. Thompson, Natarajan Raghunand, Wendy Long, Robert Macaulay, Nam D. Tran, Peter A. Forsyth, Jennifer L Dzierzeski, Timothy Robinson, Dung-Tsa Chen, John A. Arrington, Edwin Peguero, Tyra Gatewood, Heiko Enderling, Arnold B. Etame, Theresa A. Boyle, Michael Jaglal, Sepideh Mokhtari
Publikováno v:
Neuro Oncol
Background Radiotherapy may synergize with programmed cell death 1 (PD1)/PD1 ligand (PD-L1) blockade. The purpose of this study was to determine the recommended phase II dose, safety/tolerability, and preliminary efficacy of combining pembrolizumab,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc47f0e7298f717ad9d9b9d688c891ae
https://doi.org/10.1093/neuonc/noaa260
https://doi.org/10.1093/neuonc/noaa260